Hi Freeboot I agree somewhat with the statement "why continue the trials?"
My speculation is that they saw early activity and it was better in some patients than others, this was highlighted back in the ASCO presentation in Jan 24, it noted changes in responders and non responders, the difference was the T cells, they reduced in non responders,. So My theory is they are treating very sick folk who's immune system is smashed, and part of the beauty of CF33 is it invites the immune system to the fight to assist with cell killing, if the T cells are depleted not much fight left, limited response.......
Give a boost of T cells ala AZERCEL and bingo more immune cells join the fight. I reckon they saw this happening and wanted this technology at all costs hence the cap raise and all the dramas that entailed the rinse of the manufacturing plant (not needed got our agreement in place to supply) and bingo got it.
Next get it approved for use in humans, keep the MAST and OASIS trials going till we can use Azercel as well, now they showed that adding IL2 it keeps the T cells around for longer, hopefully much better bang for our buck.
Remember they only get one shot in a trial and the rules have been set about who can participate, But they have got approval to add other approved specific drugs in the Oasis trial.
Anyway my musings good luck to participants and holders the game will play out. They already have some great data and some minor wins the fact that the Nhis added to CF33 shows cancer cells affected is a big deal, PF showed a slide that showed Cancer cells "hiding in a nerve sheath which was previously undetectable" was a great find, and it showed the efficacy of CF33 Viruses ability to go after cancerous cells.
Figure 4. Changes in immune cells between responders and non-responders. (A) Differences in clusters
representing different cell populations between responders and non-responders by Uniform Manifold
Approximation and Projection (UMAP). (B) Changes in the frequencies of cells in the T and NK cell
clusters from C1D1 to C2D2
• Peripheral CD8+ T cells decreased from C1D1 and C2D2 in non-responding patients. Changes in the
expression of HLA-DR, CD38, and CD11C in T cell subsets and conventional dendritic cells (DC) were
also observed, suggesting diminished DC function and a reduction in the opportunity for antigen
cross presentation and the promotion of anti-tumor immunity (Figure 5).
Expand
(20min delay)